

Meeting Agenda	
Division:	Iowa Medicaid Enterprise Quality Improvement Organization (QIO)
Meeting Title:	Clinical Advisory Committee (CAC)
Facilitator:	Bill Jagiello, D.O.
Location:	Go To Webinar and conference call: (213)929-4212, access code: 545-151-649
Date:	July 16, 2021
Time:	1:00 p.m. – 4:00 p.m.

Meeting Objectives
<p>The purpose of the CAC is to increase the efficiency, quality and effectiveness of the Medicaid healthcare system. The CAC provides a process for physician and other healthcare provider contributions to promote quality care, member safety, cost effectiveness and positive physician and provider relations through discussion about Medicaid benefits and healthcare services.</p> <p>The CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decision to the Department of Human Services (DHS) for the Iowa Medicaid program.</p>

Meeting Participants	
Name	Organization
Bill Jagiello, D.O.	IME

Agenda Topics	Responsible Party
New Business:	
1. Introduction of new members	Dr. Jagiello
Public Comment Period	Guests

<p>Consent agenda-</p> <p>Approval of the minutes from our April meeting</p> <ol style="list-style-type: none"> 1. Back-up ventilators 2. Enteral Products and Supplies 3. Percussors 4. Pneumatic Compression Devices 5. Strollers and Wheelchairs for Safety 6. Wearable Automated External Defibrillator 7. CMH LOC- 8. Habilitation Level of Care- 9. Namenda (memantine) for Autism Spectrum Disorder 10. Crystvita (Burosumab-twza) 11. Elaprase (idursulfase) 12. Kadcyra (ado-trastuzumab emutansine) 13. Spinraza (nusinersen) 14. Zolgensma (onasemnogene abeparvovec-xioi) 15. Laser Linear Accelerator Based Stereotactic Radiosurgery 16. Reduction Mammoplasty/Mastopexy 17. Risk Reduction Mastectomy 	<p>Dr. Jagiello</p>
<p>Criteria Review</p> <ol style="list-style-type: none"> 1. Adakveo (crizanlizumab-tmca) 2. Fasentra (benralizumab) **NEW** 3. Orphan Drug (Rare Disease) Policy **NEW** 4. Sarclisa (isatuximab-irfc)**NEW 5. Trodelvy (sacituzumab govitecan-hziy) 6. Uplizna (inebilizumab-cdon) **NEW** 7. Viltepso (viltolarsen) **NEW** 8. Yescarta (axicabtagene ciloleucel) 9. Zulresso (brexanolone) **NEW** 10. Gene Expression Profiling for the Management of Breast Cancer 11. Genetic Testing for Lynch Syndrome **NEW 12. Artificial Disc Replacement **NEW** 13. Left Ventricular Assist Device **NEW 	<p>Dr. Jagiello</p>
<p>Upcoming Meetings</p> <p>October 15, 2021 January 21, 2022 April 15, 2022</p>	<p>Dr. Jagiello</p>
<p>Adjournment</p>	<p>Dr. Jagiello</p>

Contacts:

Dr. Bill Jagiello, D.O.
Medical Director
(515)974-3057
wjagiel@dhs.state.ia.us

Wendy Lathrop
Project Assistant
(515)974-2999
wlathro@dhs.state.ia.us

Guests wanting to speak during the public comment period should contact Wendy Lathrop and complete a disclosure form which is available on our website:
https://dhs.iowa.gov/ime/about/advisory_groups/clinical-advisory-group